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Although ~50% of patients with Parkinson’s disease (PD) experience depression, treat-
ment for this important and debilitating comorbidity is relatively understudied. Deep brain
stimulation (DBS) has been increasingly utilized for the management of tremors in progres-
sive PD. Several preliminary studies have shown the potential beneﬁt of DBS for non-motor
PD symptoms such as depression. Here, we critically evaluate seven recent randomized
clinical trials of the effectiveness of DBS in reducing depressive symptomatology among
individuals with PD. Findings are mixed for the effectiveness of DBS as a treatment for
depression in PD. Our review suggests that this is due, in large part, to the anatomical and
methodological variation across the DBS studies.We provide a comprehensive discussion
of these variations and highlight the need to conduct larger, more controlled studies aimed
speciﬁcally at evaluating the treatment of depression in PD patients.
Keywords: Parkinson’s disease, deep brain stimulation, depression, DBS, randomized clinical trial
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative illness found in
1–2% of individuals over age 65 in the United States (1). It
is estimated that 30–70% of PD patients experience comorbid
depression (2, 3). Symptoms of depression can begin at the ini-
tial onset of motor symptoms in PD (i.e.,resting tremor,akinesia,
bradykinesia,muscularrigidity,shufﬂingsteps,andposturalinsta-
bility) and progress over time with substantial negative effects on
overall well-being (4, 5). Depression has been linked to falls, dis-
ease progression, and negative views of PD (4). Until recently,
there has been little awareness in the medical community regard-
ing the severity and prevalence of depression in PD, and as a
result, depression in this population remains under-treated. Fur-
thermore, depression and PD have overlapping symptoms that
render them difﬁcult to identify and treat (6). For instance,symp-
toms such as “facial masking” in PD, which limits expression of
emotions, may appear to be like ﬂat affect, a characteristic of
depression. Bradykinesia due to PD could also be viewed as a
feature of depression (6).
The etiology of depression in PD is unclear. One school of
thought is that depression is a result of the progressive PD expe-
rience. However, Eskow Jaunarajs et al. (7) have suggested that
higher comorbidity between depression and PD compared to
other neurodegenerative illnesses such as multiple sclerosis (8)
and Alzheimer’s disease (9) indicates that there are other under-
lying physiological factors in play. Even when motor symptoms
improve with treatment, patients frequently continue to endorse
symptoms of depression (10). Depression is frequently the pre-
sentingsymptombeforesigniﬁcantmotorsymptomsareobserved
(11, 12). As such, it is difﬁcult to determine whether depression
is a consequence of the process of PD or of the emotional
repercussions of the disease.
Large randomized clinical trials (RCTs) examining treatment
effectsfordepressioninPDpatientsarescarce(13).Selectivesero-
toninreuptakeinhibitors(SSRIs)andtricyclicantidepressants,the
most commonly used medications for depression in PD (13),may
have beneﬁcial effects. However, SSRIs may also increase motor
symptoms and tricyclics may contribute to other non-motor
symptomssuchasdeliriumandmemorydifﬁculties(13).Another
form of treatment – electroconvulsive therapy (ECT) – has been
used to treat psychosis, refractory depression, and PD-associated
movement disorders (14); however, ECT has been found to cause
episodicconfusionandworsendyskinesia(15).Basedontheeffec-
tiveness of talk therapy for depression,such an approach could be
beneﬁcial to manage depression in PD. However, systematic psy-
chotherapeutic treatment options tailored for depression in PD
appear to have not been rigorously researched (6).
Thetreatmentof depressioninPDprecludesasystematicactu-
arialapproachandratherhasbeenfoundtobebasedonindividual
clinical opinion (13). The primary motor symptoms have been
treated with levodopa (l-DOPA) and more invasive treatments
such as deep brain stimulation (DBS). l-DOPA, a dopamine ago-
nist has been widely accepted as the leading medical treatment
for the motor symptoms of PD; nevertheless, it is often limited in
controllingprogressivesymptomsrelatedto“gait,balance,speech,
swallowing,and cognition”in refractory PD (16).
Asaresult,DBShasbeenincreasinglytestedandutilizedforthe
management of tremors in progressive PD (17–19). Several recent
preliminarystudieshaveshownthepotentialforshort-termutility
(i.e., effects lasting 6–12months post-surgery) of DBS in PD for
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depression(20–24).Despitetheseinitialﬁndings,allof thestudies
werelimitedforseveralreasonsincludingsmallsamplesizes,acase
or cohort design, or a lack of randomization and further longitu-
dinal follow-up. Given that RCTs are regarded as the benchmark
for informing subsequent clinical treatment, the purpose of this
review is to evaluate the most recent RCTs of the effectiveness of
DBS in reducing depressive symptomatology among individuals
with PD.
LITERATURE REVIEW
PHYSIOLOGICAL BASES OF PARKINSON’S DISEASE
Parkinson’s disease is primarily associated with the loss of
dopaminergic cells in the substantia nigra pars compacta (SNPC),
located in the basal ganglia. The SNPC dopaminergic projections
regulate both the direct and indirect motor-control pathways in
the basal ganglia (25). When these SNPC dopaminergic neurons
arelost,theoutputof thebasalgangliaincreases,leadingtoaltered
activity in the thalamus and neocortex (25), and resulting in the
motor deﬁcits typically observed in PD (26).
Levodopa increases the diminished dopamine concentrations
in the basal ganglia (27), which explains why it is the most widely
used PD medication. However, it can have a multitude of side
effects and poses a risk for developing additional motor-related
disabilities (28). Furthermore, as the disease progresses, l-DOPA
treatment tends to lose its efﬁcacy, while a number of complica-
tions(suchasdyskinesia)maydevelop,probablyduetoprogressive
dopaminergic neuronal loss (28). Such complications occur in
approximately half of the patients 5years after treatment initia-
tion and in ~80% of patients after 10years of treatment (29, 30).
Dopamine loss may also be involved in the onset of depression
in PD (7). Clinical ﬁndings indicate that l-DOPA treatment does
not necessarily improve mood and, in fact, may exacerbate mood
symptoms (7) by further disturbing the function of the norepi-
nephrineandserotoninsystems,alreadyaffectedbyPDpathology.
Eskow Jaunarajs and colleagues (7) reviewed four studies (31–34)
with samples ranging from 23 to 422 patients in the latter realm.
Findings indicated that patients undergoing l-DOPA treatment
remained depressed or did not see a signiﬁcant improvement in
their depression. Several other studies have also indicated that PD
patients with depression are more likely to receive higher doses
of l-DOPA compared to PD patients without depression (35,36).
In summary, although l-DOPA is essential for managing motor
symptoms,increasesindepressionmaybeapotentialconsequence
of this treatment in patients with PD.
DEEP BRAIN STIMULATION
Deep brain stimulation is a surgical treatment in which one or
more electrodes are implanted in the basal ganglia, typically tar-
geting either the subthalamic nucleus (STN) (37) or the globus
pallidus interna (GPi) (38). The electrodes are connected to
a stimulator, which delivers high-frequency electrical pulses in
order to alter patterns of neuronal signaling within the targeted
region (16).
Imaging and clinical studies on STN DBS show changes in
neuronal activity in the frontal lobe and the limbic system (39)
and changes in frontal lobe function, respectively (40, 41). As
such, in addition to improving motor function, STN DBS can
affect frontal-lobe-dependent executive functioning, attention,
emotions, and memory, all functions negatively impacted by a
depressive syndrome (23).
CLINICAL FINDINGS
Overall, the preliminary ﬁndings regarding the effectiveness of
DBS surgery on mood in PD have been mixed. A meta-analysis
(42) reviewing 82 studies evaluating behavioral outcomes in PD
patients after undergoing STN DBS surgery found that 8% of
the total sample (N D1398) had depression after DBS treat-
ment. Depression typically reduced after“adequate”psychotropic
treatment (the speciﬁcs of treatment were not provided by the
authors); however, 4% of the depressed patients subsequently
attempted suicide (42). Therefore, a patient may have still met
criteria for depression post-treatment but also have experienced
a substantial decrease in symptoms. Although these small dif-
ferences in symptom reduction may not reach statistical sig-
niﬁcance, clinically speaking, these differences may still have a
positive impact on the patient’s functioning. The authors did
not report outcome measures or potential premorbid depres-
sion levels so it is important to use caution in interpreting these
ﬁndings.
In a structured review of 23 cohort and case studies found
that depression reduced or remained unchanged after STN DBS
within the ﬁrst year of surgery, whereas little effect on depres-
sion level was observed after any of the other procedures [i.e.,
Ref. (23)]. A separate study assessed 33 patients, after undergoing
STN DBS, ﬁnding that symptoms of depression decreased signif-
icantly (p D0.007) post-surgery up until the ﬁrst year and then
returning to pre-surgery level at year 3 (43). In contrast, Castelli
and colleagues (44) found that depression at the 3-year follow-
up visit did not improve in the STN DBS group compared to an
l-DOPA control group who did not undergo DBS surgery. Col-
lectively,non-RCT ﬁndings potentially indicate short-term mood
improvement after DBS.
METHODS
A literature review search was conducted via Google Scholar and
PubMed through March 2013 employing the following combina-
tion of key words: DBS, depression, and Parkinson’s; DBS, mood,
andParkinson’s;DBS,Parkinson’s,andpsychiatricoutcomes;clin-
ical trials, DBS, depression, and Parkinson’s. Inclusion criteria
comprise studies written in English and studies looking at symp-
toms of depression as one of their outcome measures. Exclusion
criteria included any studies that were non-RCTs. Seven original
researcharticlesmettheinclusioncriteriaandwereconsideredfor
the review (45–51).
RESULTS
Four research groups (based in Argentina, Germany/Austria,
and the United States) conducted the seven studies (N D889)
reviewed. Table 1 reports study characteristics and ﬁndings.
In the Weaver et al. study (48), those who were randomized
to the DBS group were then again randomized to receive either
STN (n D60) or GPi (n D61). The study found statistically non-
signiﬁcantreductionsof depressionscoresindicatedbya1.5mean
reductioninthemedicaltreatmentgroup(n D134)comparedtoa
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Table 1 | Randomized clinical trials included in the present review.
Author Location Sample
size
Intervention Outcome
measure
Findings p Values and
effect size
Okun et al. (45) USA 110 Unilateral STN DBS vs.
unilateral GPi DBS
Assessment at baseline and
6-months post-surgery
BDI Those with pre-DBS
depression had signiﬁcantly
higher BDI scores than
non-depressive group after
both treatments
p D0.04
Follett et al. (46) USA 299 Bilateral STN DBS vs. bilateral
GPi DBS
Assessment at baseline and
24-months post-surgery
BDI Depression improved for GPi
and worsened for STN
p D0.02
Okun et al. (47) USA 45 Unilateral STN DBS vs.
unilateral GPi DBS
Assessment at baseline and
6-months post-surgery
BDI No differences between STN
and GPi
Overall improvement in both
groups
p D0.30
ns
Weaver et al. (48) USA 255 Medical treatment vs.
Bilateral STN DBS
Assessment at baseline and
6-months post-tx
BDI No signiﬁcant group
differences
Both groups indicated
minimal symptom reduction
p D0.22
Zahodne et al. (49) USA 42 Unilateral STN DBS vs.
unilateral GPi DBS
Assessment at baseline and
6-months follow-up
BDI No signiﬁcant group
differences
ns
Merello et al. (50) ARG 15 Bilateral STN DBS vs. bilateral
subthalamotomy (BL) vs.
unilateral subthalamotomy
plus correlateral
implementation STN DBS
Assessment at 1-month
before, and 6 and 12-months
post-surgery
HAM-D No signiﬁcant group
differences
p <0.7 , 0.9, 0.8
(pre-surgery, 6, and
12months post-surgery,
respectively)
Witt et al. (51) GER 123 Medical treatment vs.
bilateral STN DBS
Assessment at baseline and
6-months post-tx
BDI
MDRS
Depression improved
“slightly” for DBS group on
both measures
p D0.06, Cohen’s
d D0.2
p D0.07 , Cohen’s
d D0.3
BDI, Beck depression inventory; HAM-D, Hamilton depression scale; MDRS, Montgomery–Asberg depression rating scale; ARG, Argentina; GER, Germany; USA,
United States; STN DBS, subthalamic nucleus deep brain stimulation; GPi DBS, globus pallidus pars interna deep brain stimulation; ns, not signiﬁcant.
0.4pointmeanreductioninthetotalityoftheDBSgroup.Separate
scores for the STN and GPi DBS groups were not provided.At the
6-month follow-up, both DBS groups reported more depression
compared to best medical treatment group.
In contrast, Witt and colleagues (51) found that depression,
although not statistically signiﬁcant, minimally improved in the
bilateralSTNDBSgroup(n D63)relativetothemedicaltreatment
group (n D60) indicated by small effects on both self-reported
and clinician-administered measures of depression at 6-months
follow-up. Moreover, 13% of the DBS group and 10% of the
medical treatment group experienced severe psychiatric adverse
events that included suicide, “death during a psychotic episode”
(the speciﬁcs were not provided), psychosis, and depression. Of
those,fourDBSparticipantsendorseddepressionbuttheirepisode
was in remission by follow-up.
In a single blind study with the largest sample (46) compared
to the other reviewed studies [and with the same recruitment
methods described in Ref. (48)], those in the bilateral GPi DBS
group (N D152) had a mean reduction of 0.6 points whereas
those in the STN DBS group (N D147) had a mean increase of
1.3 points on symptoms of depression at the 24-month follow-
up. One patient who underwent GPi DBS committed suicide,two
patients undergoing STN DBS attempted suicide, and one other
patientundergoingSTNDBShadsuicidalideation.Therewereno
signiﬁcantgroupdifferencesintermsofexperiencingsuchadverse
events.
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In another study (47), both unilateral STN DBS (N D22) and
GPi DBS (N D23) groups showed an overall mean reduction in
symptoms of depression (MD 3.7, SDD5.9); however, there
were no signiﬁcant differences between treatment groups at the
7-month follow-up. Mood-related adverse events including anx-
iety, irritability, aggressiveness, obsessive–compulsive symptoms,
manic symptoms, and decreased motivation were more frequent
intheSTNgroup(N D75)vs.theGPigroup(N D45),indicating
that, overall, patients were experiencing multiple events.
In a retrospective study, Okun et al. (45) compared those with
a diagnosis or history of depression (N D40) and those without
premorbid depression (N D70) at a 6-month follow-up who had
eitherreceivedunilateralSTNDBSorunilateralGPiDBS.Patients
with premorbid depression were signiﬁcantly more depressed at
follow-upcomparedtothosewithnopriordepression.Differences
in mood symptoms at follow-up were not reported between STN
DBS and GPi DBS groups.
The fourth and last unilateral STN DBS (N D20) vs. unilat-
eral GPi DBS (N D22) study (49) found that for both treatment
groups, depression signiﬁcantly improved at the 6-month follow-
up visit (p <0.001). The GPi group showed a slightly larger mean
reduction ( 4.6 points) compared to that showed by the STN
group ( 2.6 points), but there were no signiﬁcant group differ-
ences. Participants were recruited as part of a larger trial (47)
described earlier.
Intheﬁnalstudyof thepresentreview(50),thethreetreatment
groupsincludedbilateralSTNDBS(N D5),bilateralsubthalamo-
tomy(BL)(N D5),andunilateralsubthalamotomypluscontralat-
eral STN DBS (L/S) (N D5). There were no treatment effects on
symptoms of depression at any follow-up time point. Reportedly,
two patients in the bilateral STN group presented with irritabil-
ity, excitation, paranoia, and insomnia post-surgery but returned
to baseline level after stimulation adjustments were made. In
addition, one other patient presented with “severe apathy” that
necessitated ongoing treatment.
DISCUSSION
Overall,ﬁndingsaremixedwithregardstotheeffectivenessofDBS
as a treatment for depression in PD. Furthermore, it is unclear
whether treatment effects are maintained long-term given the
paucity of longitudinal research exceeding 1-year of follow-up.
Limited ﬁndings based on the present review and previous
studies (52–54) indicated that GPi DBS may appear to be slightly
safer compared to STN DBS because mood-related adverse events
including suicide appear tobe less common.An earlier pilot study
(24) evaluated nine patients (ﬁve underwent unilateral STN DBS
andfourunderwentunilateralGPiDBS).Stimulationatthesiteof
optimal motor performance was linked to mood symptom reduc-
tion in both DBS treatments (24). However, overall, the GPi DBS
group showed slightly increased symptoms compared to the STN
DBS group (24). In contrast, Follett and colleagues (46) reported
that GPi DBS minimally improved depression symptoms whereas
STN minimally worsened it. One hypothesis for this difference
in mood outcome relates to their anatomical size. The STN is
smaller than the GPi, and, as a result, may be more vulnerable
to surgical injury leading to a greater likelihood of post-surgery
mood-related issues (47). However, differences among the ﬁbers
of passage coursing near the STN vs. GPi may also help to explain
the differences between stimulation of the two regions.
Certainly,itisconcerningthatstudiesevaluatingadverseevents
occurring in STN DBS have reported suicide attempts after
surgery. One international multi-center review (55) found that
retrospectively observed suicide rates after DBS STN surgery were
higherthantheexpectedage,gender,andcountry-adjustedsuicide
ratesandcontinuedtobehighatthefourthpost-surgeryyear(55).
The most signiﬁcant predictor of attempted and completed sui-
cide was found to be post-surgery depression (55). As such, those
individualsweremorelikelytohavehadpre-surgerydepressionas
well (55). Mood-related complications after DBS are unclear and
multiple confounding factors are potentially involved, including
pre-DBS psychiatric symptoms (56), the surgery itself (57), the
different types of electrical stimulation (58), adjustments in psy-
chosocial functioning post-DBS (59), and the disease progression
of PD (60).
STRENGTHS
There were several consistencies in the reviewed studies. Speciﬁ-
cally, pre and post-treatment change in symptoms of depression
were reported. All studies were blinded, RCTs with at least one
follow-up time point and all studies with the exception of one
includedtheBeckDepressionInventoryastheiroutcomemeasure.
The reviewed studies show preliminary evidence toward ﬁne-
tuning DBS surgery to help improve depressive symptoms that
are highly associated with a debilitating disease, thus, providing
hope for improving quality of life.
LIMITATIONS
TheresultsfromtheexistingRCTsshouldbeinterpretedwithcau-
tion because of primarily methodological limitations including
small sample sizes, relatively short follow-up (6–12months), and
possiblepublicationbiasduetoscantresearchinthisarea.Depres-
sion can have various etiologies. Given that all reviewed studies
were part of larger clinical trials, and assessing mood symptoms
typically was a secondary goal of the studies, previous diagnosis
of depression and psychotropic medication history were not dili-
gently reported. Also, none of the studies examined the use of
psychotropic medication, talk therapy, or ECT as control or com-
parison groups, treatments that have been found to be effective
with stand-alone depression.
Other possible reasons for the variation in the results may be
due to the different levels of l-DOPA used at different time points
between studies that may have impacted depression as well as the
inconsistency of the brain regions stimulated by DBS. By nature
of thesurgery,surroundingbrain regions suchas thelateral hypo-
thalamus and ventral tegmentum connected to the limbic system
canbeaffectedbytheelectricalstimulationand,hence,affectthose
areas that play a role in processing emotion (61).Additionally,the
axons of neurons in distant cortical regions that send projections
to the STN can also be activated by the high-frequency electri-
cal pulses used in DBS (62). This highlights the importance of
systematically dissecting the precise neuronal targets of DBS.
FUTURE RESEARCH
Given the mixed ﬁndings and limitations in the research con-
ducted so far, it is problematic to conclude what the current best
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practiceshouldentailwithregardstoDBSsurgery.Thereisemerg-
ing evidence suggest that the DBS target choice may be tailored to
individual patient needs (16). When depression is of concern, the
beneﬁtsassociatedwithGPistimulationmaypotentiallyoutweigh
the risks associated with STN DBS. As more RCTs are conducted,
it will enable tailored target selection based on need and risk
proﬁles (16).
Irrespective of etiology,depression should be consistently eval-
uated and treated by health care providers. One approach is to
measure depression prior to treatment with PD medications and
then measure the change in depression after PD medications have
been administered (6). Assessing reliabilities in clinical response
to depression in PD could allow some indication of when to treat
depression as part of PD itself and when to treat depression as a
separate syndrome (6).
Furthermore, one important clinical recommendation is, in
addition to neuropsychological evaluation, an initial structured
psychiatric assessment should be conducted for each newly diag-
nosed PD patient to serve as a baseline that can later be utilized if
the patient does indeed opt for DBS.
Future interventions should aim to enroll larger sample sizes,
control for premorbid/pre-surgery mood disorders, and consis-
tently compare both within group variability and between group
variability. Interventions should provide longitudinal follow-
up visits after surgery to examine long-term protective effects
of DBS.
A ﬁnal thought is that a shift in perspective of depression
in PD in the medical ﬁeld is warranted. Thus, a comprehensive
assessment of symptoms of depression guided by current research
should be conducted when working with individuals with PD to
better inform treatment protocols.
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